Analyst Price Target is $97.46
▲ +61.31% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Arena Pharmaceuticals in the last 3 months. The average price target is $97.46, with a high forecast of $120.00 and a low forecast of $76.00. The average price target represents a 61.31% upside from the last price of $60.42.
Current Consensus is
The current consensus among 12 investment analysts is to buy stock in Arena Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.